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Abstract

Background: Recurrent aphthous ulcers (RAU) are common painful inflammatory lesions of the mucous lining of
the mouth. Endocan, previously identified as endothelial cell specific molecule-1, is implicated as a vital player in
the regulation of several inflammatory processes. A number of inflammatory cytokines and pro-angiogenic growth
factors including VEGF upregulate endothelial cells synthesis and expression of endocan.
Material and Methods: Clinical scores of pain and ulcer size as well as level of endocan and VEGF were determined
in swaps from aphthous ulcer and contra lateral normal mucosa in 30 patients (nine males and twenty one females)
with age ranging from 18 to 45 years and mean age is 31.5 years.
Results: In the early days of ulcer development, ulcer showed statistically significantly higher mean endocan (8.2
±5.3) and VEGF levels (1220.7 ±294.6) than control healthy mucosal site (1.1 ±0.5) and (518.6 ± 61.7) respectively. An increase in endocan is associated with an increase in pain score and vice versa. A statistically significant
positive correlation were also found between endocan and VEGF levels.
Conclusions: Endocan and VEGF are strongly associated with the destructive phase of minor aphthous ulcers especially Endocan which was positively correlated with pain severity.
Key words: Endocan, ESM-1, VEGF, Recurrent Apthous Ulcer.

Introduction

the first occurrence being in early childhood or even in
later (2). The decreased occurrence of RAU in elderly
may be due to age-dependent variations in the acquired
and innate immune systems, designated as immunosenescence (3).

Recurrent aphthous ulcers (RAU) is the most communal
inflammatory ulcer affecting the oral mucosa (1) with
the prevalence of 5 - 25 % in the overall population. The
peak period of RAU occurs in the second decade and
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Based on the clinical presentation, three forms of RAU
can be designated: minor, major or herpetiform aphthous
ulcers. The minor type is the most common affecting
about 80% of patients (1). It occurs as round or oval ulcers <1 mm in diameter affecting non-keratinized mucosa as the buccal and labial mucosa and floor of mouth
with the floor covered by a grayish white pseudomembrane and is surrounded by a halo of erythema. The ulcers usually heal in 10–14 days with no scarring (4).
Thus far, the etiopathogenesis of this disease remains
uncertain and seems to be multifactorial. The possible
risk factors that could trigger the condition include: food
allergies, vitamin deficiencies, genetic predisposition,
bacterial and viral infections, systemic ailments (e.g., ulcerative colitis, Crohn’s disease, celiac disease, AIDS),
hormonal disorders, amplified oxidative stress, mechanical irritation and stress (5-7).
The most accepted theory regarding the aetiology of RAU
is that these predisposing factors or unknown antigenic
stimulation triggers oral mucosal keratinocytes to transform into a target of the uncontrolled action of lymphocytes, neutrophils and monocytes resulting in liberation
of acute inflammatory mediators, damage of oral mucosal
cells, thus the appearance of an aphthous ulcer (8,9).
The acute inflammatory mediators liberated during the
initiation of the ulcerative process that included cytokines for instance TNF-α, IFN-ϒ, IL-2 and IL-2, along
with the migration of other lymphocytes, langerhans
cells and neutrophils also causes an over expression of
Vascular Cell Adhesion Molecules (VCAM), Intercellular Adhesion Molecules (ICAM-1) and Selectine E leading to more lymphocytic accumulation and invasion of
the epithelium locally (10).
Vascular endothelial growth factor (VEGF) is a powerful
endothelium-specific cytokine that effectively stimulates angiogenesis, inflammation, endothelium-dependent
vasodilatation and amplified microvascular permeability
(11). It is principally produced by vascular endothelial
cells, macrophages and neutrophils. In inflammatory reactions its production is stimulated, and VEGF itself endorses the inflammatory processes. An increase in VEGF
levels have been described in several inflammatory and
autoimmune diseases (12,13). In their study, Arbiser et
al. (14) reported elevation in VEGF levels in addition to
its receptors in RAU and advocated that oral aphthous
ulcerations might be highly angiogenic.
Endocan is a unique human endothelial cell- specific
molecule (ESM). It was initially cloned from a human
endothelial cell DNA library by Lassalle et al. (15). Endocan is secreted by epithelial cells of the renal distal
tubules, vascular endothelial cells, bronchi and lung sub
mucosal glands (16). A number of cytokines and growth
factors regulate the expression of endocan by vascular
endothelium. Binding of endocan to human leukocytes
occurs via the integrin leukocyte function-associated an-

tigen (LFA)-1 and hinders the interactions of LFA- 1/
intercellular adhesion molecule (ICAM)-1 and, possibly,
LFA-1-mediated leukocyte functions (17). Endocan expression has been reported to be intensely up-regulated
via proangiogenic molecules as VEGF-A and VEGF-C
which are known to be critical mediators of lymphangiogenesis, angiogenesis, and cancer progression (18).
To the best of our knowledge, there is no previous study
investigating the association of endocan and VEGF
in recurrent aphthous ulcers. Therefore, in the present
study, we aimed to investigate the expression levels of
Endocan and VEGF in minor aphthous ulcer lesions during both the active and the healing stages.

Material and Methods

This study was conducted in Faculty of Dentistry, Cairo
University after approval of the faculty Research Ethics
Committee.
Thirty subjects (nine males and twenty one females)
were recruited from outpatient clinic of Oral Medicine,
and Periodontology Department, Faculty of Dentistry,
Cairo University.
Inclusion criteria included patients having minor aphthous ulcers with no other specific pathology affecting
the oral mucosa. The patients were systemically free
according to Cornell medical index. The appearance of
the ulcers should not be more than 3 days at the time of
enrolment in this study.
Exclusion criteria included: patient with any systemic
disease producing oral ulcerations as Bechets disease,
ulcerative colitis, Reiter syndrome, haematological diseases, Cohns disease, allergic conditions, nutritional
deficiencies, in addition to patients who have received
any medical treatment in the past six months, pregnant
or lactating mothers and smokers.
During the period of clinical study, the subjects had not
to use any topical agents such as mouth wash and topical
medication for treating aphthous ulcer and avoid taking
spicy foods, sour drinks and coffee. Patients were informed of the nature and objectives of the study and they
were educated about importance to come for the follow
up visits till the end of the study. After that the enrolled
patients signed a written informed consent.
Clinical evaluation of the patients:
1. Recording of pain score:
Assessment of pain was done via Visual Analogue Scale (VAS) that is comprised of a 10 cm line enclosing
equidistant subdivisions of the following concomitant
scores: randling.
Score 0 = no pain
Score 1 = pain with rough aggravation
Score 2 = pain with moderate aggravation
Score 3 = pain with slight aggravation
Score 4 = constant pain
Score 5 = severe pain
e535
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Patients were informed that aggravation referred to
anything that may move or touch the ulcer area and also
that pain associated with gentle touching of the lesion
was greater than that of rough handling.
Pain scores were assessed 2 times; in the second and the
tenth day of the ulceration period. Pain scores were plotted in a table and compared in the study site statistically.
2. Assessment of ulcer size as follows:
Under good lightening conditions, the ulcer area was
dried carefully then a transparent plastic sheet was cut to
facilitate its application directly on the ulcer. Then using
a permanent water proof marker pen, the circumference
of the ulcer was traced on the plastic sheet. The tracing
was then placed on graph paper and the size of the ulcer was calculated in mms. Ulcer sizes were assessed 2
times; in the second and the tenth day of the ulceration
period. The sizes of the lesions were plotted in a table
and compared in the study site statistically.
Exfoliative cytology and preparation of smears:
Swabs were taken from the ulcer at the second and tenth
days of the ulceration period as well as from the contralateral healthy mucosa to assess the level of Endocan
and VEGF.
The sampling procedure was done as described previously by Spafford et al. (19). Aphthous ulcers were
cleaned slowly with a cotton wetted by saline and then
the ulcers were swabbed with a sterile cotton roll. This
technique was applied by a stroke of the mucosa 3 to 5
times to collect the cell exfoliations. In addition, swabs
from the contralateral clinically unaffected mucosa were
obtained from all subjects as well to compare the level of
Endocan and VEGF in the ulcer and the healthy mucosa.
After swabbing of the ulcer and mucosa by the cotton
roll, the sample was allowed to dissolve in an eppendorff
tube containing Phosphate Buffered Saline (PBS) solution. Samples were then stored at – 70O C until being
used for laboratory analysis.
Assessment of Endocan and VEGF:
Endocan Assay:
Endocan was measured using ELISA kit supplied by
EIAab, China Catalogue No: E2112h. This kit allows
for the in vitro quantitative determination of human Endocan concentrations in serum, tissue homogenates and
different biological fluids. The microtiter plate of the kit
has been pre-coated with an endocan specific antibody.
This is followed by addition of samples and standards
to the microtiter plate wells with a biotin-conjugated
polyclonal endocan specific antibody. Horseradish Peroxidase (HRP) is then added to and incubated in the
microplate well. Then substrate solution (TMB) is added
to all wells. The reaction is finished by the addition of a
stop solution of sulphuric acid and the color intensity is
measured by spectrophotometer at a wavelength of 450
nm ± 2 nm. The Endocan concentration in the samples is
specified from the standard curve.

VEGF Assay:
The concentration of VEGF was determined by a quantitative sandwich enzyme immunoassay kit (R&D Systems, Minneapolis, MN.) according to manufacturer’s
directions. Briefly, 100 ml assay diluent RD1W was
added to each well. After dilution of samples, 100 ml
sample was added per well. It was covered with the adhesive strip provided and incubated for 2 hours at room
temperature. Aspiration and washing for each well was
done and repeated twice for a total of three washes. A
total of 200 ml VEGF conjugate was added to each well,
covered with a new adhesive strip, and incubated at
room temperature for 2 hours. Aspiration and washing
was repeated. A total of 200 ml substrate solution was
added to each well, protected from light, and incubated
at room temperature for 25 minutes. Then, 50 ml stop
solution was added to each well. The plate was gently
tapped to confirm complete mixing. Assessment of optical density of the wells was done within 30 minutes
via a microplate reader set to 450 nm. VEGF levels in
samples were appraised via the standard curve plotted
utilizing the optical density values with the standards.
Samples and standards were assayed in duplicate as recommended by the manufacturer.
-Statistical Analysis
Data were presented as mean, standard deviation (SD), median and range values. Data were explored for normality
by checking the data distribution, calculating the mean and
median values and using Kolmogorov-Smirnov and Shapiro-Wilk tests. All data showed non-parametric distribution.
The study is a split-mouth design; so Wilcoxon signed-rank
test was used to study the changes after treatment as well as
to compare between ulcer and control sides.
Spearman’s correlation coefficient was used to determine significant correlation between different variables.
The significance level was set at P ≤ 0.05. Statistical
analysis was performed with IBM® SPSS® Statistics
Version 20 for Windows.

Results

The present study included a total of thirty subjects (nine
males and twenty one females). The mean ± standard
deviation (SD) values of age were 33.2 ± 10.2 years with
a minimum of 18 years and a maximum of 45 years old.
Comparison of the different variables between the second day and the tenth day
Pain score and ulcer size:
The pain and ulcer size were recorded at the second day
and again at the tenth day of ulcer period. Pain score
decreased significantly from 3.6 ± (0.9) at the second
day to 1.0 ± (0.7) at the tenth day with p-value <0.001*.
The same was observed with the ulcer size which was
35.1 ± (9.8) mm2 at the second day and significantly reduced to 11.6 ± (5.8) mm2 at the tenth day with p-value
<0.001* (Table 1).
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Table 1: Descriptive statistics and results of Wilcoxon signed rank test for the changes in different variables.

Variable

At the second day

At the tenth day

P-value
<0.001*

Pain
Mean (SD)
Median (Range)

3.6 (0.9)

1.0 (0.7)

3.5 (2.0 – 5.0)

1.0 (0.0 – 2.0)

35.1 (9.8)

11.6 (5.8)

35.5 (19.6 – 50.3)

11.8 (3.1 – 19.6)

8.2 (5.3)

1.9 (1.1)

6.4 (2.4 – 20.5)

2.0 (0.4 – 4.2)

1220.7 (294.6)

788.5 (152.0)

1137.5 (826.0 – 1698.0)

764.0 (537.0 – 1025.0)

Ulcer size (mm2)
Mean (SD)
Median (Range)

<0.001*

Endocan (pg/ml)
Mean (SD)
Median (Range)

<0.001*

VEGF (pg/ml)
Mean (SD)
Median (Range)

<0.001*

*: Significant at P ≤ 0.05.

Endocan and VEGF level:
At the second day of ulcer activity, the ulcer swabs
showed statistically significantly higher mean endocan
levels 8.2 ± (5.3) pg/ml than those at the tenth day 1.9
± (1.1) pg/ml with p-value <0.001*. Similarly, the ulcer swabs showed statistically significantly higher mean
VEGF levels at the second day of ulcer activity 1220.7 ±
(294.6) pg/ml than those at the tenth day 788.5 ± (152.0)
pg/ml with p-value <0.001* (Table 1).
Comparison of Endocan and VEGF level between study
and control sides
At the second day of ulcer activity, the ulcer swabs
showed statistically significantly higher mean endocan
and VEGF levels 8.2 ± (5.3) and 1220.7 ± (294.6) pg/
ml respectively than those of the healthy mucosa 1.1 ±
(0.5) and 518.6 ± (61.7) pg/ml respectively with P-value
< 0.001 and < 0.001, respectively. Similarly, during hea-

ling at the tenth day; the ulcer swabs showed statistically significantly higher mean endocan and VEGF levels
1.9 ± (1.1) and 788.5 ± (152.0) pg/ml respectively than
those of the healthy mucosal site 1.1 ± (0.5) and 518.6±
(61.7) pg/ml respectively P-value = 0.009 and < 0.001,
respectively (Table 2).
Correlation between different variables in the study side
At the second day, there was a statistically significant positive (direct) correlation between endocan and pain score;
i.e. an elevation in endocan is associated with an elevation
in pain score and vice versa (Fig. 1). There was also a statistically significant positive (direct) correlation between endocan and VEGF; i.e. an elevation in endocan is associated
with an elevation in VEGF and vice versa (Fig. 2).
No statistically significant correlation was found between (endocan and ulcer size), (VEGF and pain score)
as well as (VEGF and ulcer size).

Table 2: Descriptive statistics and results of Wilcoxon signed-rank test for comparison between study and control sides.

Time
At the second day

At the tenth day

*: Significant at P ≤ 0.05.

Variable

Ulcer side

Healthy side

P-value

Endocan (pg/ml)
Mean ± (SD)

8.2± (5.3)

1.1± (0.5)

<0.001*

VEGF (pg/ml)
Mean ± (SD)

1220.7 ± (294.6)

518.6 ± (61.7)

<0.001*

Endocan (pg/ml)
Mean (SD)

1.9± (1.1)

1.1 ± (0.5)

0.009*

VEGF (pg/ml)
Mean ± (SD)

788.5± (152.0)

518.6± (61.7)

<0.001*
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Fig. 1: Scatter diagram representing direct correlation between endocan and pain scores at second day.

Fig. 2: Scatter diagram representing direct correlation between Endocan and VEGF at second day.

At the tenth day, there was no statistically significant correlation between any of the different variables (Table
3).

the role of the autoimmunity in the disease development.
Disturbance of acquired as well as innate immune response may occur in patients with RAU demonstrated as
elevated levels of the complement proteins, neutrophils
hyper-reactivity, elevated amount of B lymphocytes and
NK cells, in addition to disruption of the CD4/CD8 ratio
and elevated amount of T cell receptor (TCR) and CD25
cells in peripheral circulation (11,22).

Discussion

Although the exact aetiology of RAU is unknown, several investigations have suggested immunodysregulation
in this patients (2,20,21). Many studies also emphasized
e538
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Table 3: Results of Spearman’s correlation coefficient for the correlation between different variables.

Time
At the second day

At the tenth day

Variables

Correlation coefficient (r)

P-value

Endocan and pain score

0.693

0.001*

Endocan and ulcer size

-0.325

0.163

Endocan and VEGF

0.666

0.001*

VEGF and pain score

0.350

0.130

VEGF and ulcer size

-0.112

0.639

Endocan and pain score

0.320

0.170

Endocan and ulcer size

-0.321

0.167

Endocan and VEGF

0.176

0.457

VEGF and pain score

0.172

0.469

VEGF and ulcer size

-0.356

0.124

*: Significant at P ≤ 0.05.

Endothelial cells are in charge of leukocytes attraction
which are recruited early in inflammatory response (23).
The Th1 immunologic response is suggested by many
authors to have a crucial role in the progression of RAU
(20,21,24). This was supported by Lewkowicz et al. (25)
who reported a significant increase of Th1 cytokines in
RAU patients in contrast to healthy subjects.
Vascular endothelial growth factor (VEGF) is produced
by platelets and plays an imperative role in proteolytic
enzyme secretion, proliferation of endothelial cell, and
cell emigration via chemotaxis; in addition to its angiogenesis stimulating function (26).
Endocan, a soluble proteoglycan secreted by vascular
endothelial cells and it is primarily regulated by various
inflammatory cytokines as IL-1 and TNF-a. In addition
to VEGF-A which is also implicated in the action of endocan. Moreover, some experimental studies proposed
endocan as a strategic regulator of inflammatory disorders, cellular adhesion, and cancer development. Therefore, it is considered an endothelial immunoinflammatory marker (17,27).
To the best of our knowledge, the present research is the
first to evaluate the role of endocan in the pathogenesis
of recurrent aphthous ulcer.
The present research aimed to evaluate the pain severity,
ulcer size, and cytological profile of both endocan and
VEGF in RAU in the active phase at the second day and
in the healing phase at the tenth day. Pain score as well
as ulcer size were found to significantly decrease from
the second day of ulcer development to the tenth day.
Both findings are consistent with the self-limiting nature of RAU aphthous in which healing usually occurs
within 10-14 days (2). Accordingly at day ten ulcers had

already entered the healing phase with reduction in ulcer
size and consequently pain score being a symptom of
active destruction .
Since no previous studies evaluated endocan levels in
oral exfoliative cytology specimens in aphthous ulcers,
it is hard to compare our results directly with other researches. However, several studies reported a significant
increase in serum level of endocan in other inflammatory
disorders as septic shock (28), psoriasis vulgaris (29),
cardiovascular events (17) and chronic kidney disease
(30). Other studies reported that endocan level can be
elevated in malignancies, however the regulation of its
secretion and synthesis carried out via proinflammatory
cytokines, as well as angiogenic factors like VEGF
(31,32).
Moreover, endocan has been strongly associated with
Behçet Disease which is an inflammatory condition
characterized by more than 95% occurrence of oral aphthous like ulcers (33).
Findings of the present study showed that mean levels
of endocan was statistically significantly higher in oral
RAU lesions than control side either at second day or at
day ten. Moreover, the ulcer swabs showed statistically
significantly higher mean endocan levels at the second
day of ulcer activity than those at the tenth day during
the healing phase indicating the strong association of endocan with acute destructive phase of the disease.
Balta et al. (27) reported that endocan levels in serum
of Behçet Disease patients were significantly higher
than control and discovered that serum endocan levels
directly correlated with erythrocyte sedimentation rate,
C-reactive protein, and with disease activity. Moreover,
endocan levels were greater in patients suffering from
e539
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systemic manifestations, and they concluded that endocan may impact both endothelial function and the inflammatory process through the pathogenesis of Behçet
Disease and attributed the elevated endocan levels found
in those patients to the LFA-1/ICAM- 1 pathway inhibition; and stimulation of endocan expression by the raised VEGF plasma levels in Behçet Disease patients (34).
Additionally our results revealed a statistically significant positive (direct) correlation between endocan levels
and pain score, where an increase in endocan level was
associated with an elevation in pain score and vice versa
indicating that endocan is more strongly associated with
disease severity and active destructive phase of minor
aphthous ulcers.
The higher level of endocan can be explained by the fact
that many of cytokines and growth factors regulate its
expression (17). Where it was found that TNF-α and IL1β and VEGF had been shown to prompt endocan expression (35). Since it has been reported that such cytokines and growth factors are directly involved and may
be overexpressed during the destructive process of oral
aphthous ulcer (2,10). Consequently this could explain
the elevated endocan levels encountered in RAU lesions
in the present study.
Another explanation is that endocan may be involved
in regulating leukocyte extravasation at sites of inflammation, due to the importance of the ICAM-1/LFA-1
interactions for secure adhesion of monocytes and lymphocytes. In addition, endocan could modify the LFA-1/
ICAM-1 co-stimulatory pathway on T cells and could
modulate the balance of Th1/Th2 in the immune response (34). Such balance is disturbed favoring Th1 type
immunologic response which is proposed by many authors to play the fundamental role in RAU development
(21,22,25) reflecting a conceivable connection of endocan to the pathogenesis of RAU.
The present study also investigated the levels of VEGF in
oral RAU due to its relation to endocan as endocan synthesis is enhanced during inflammatory processes, and VEGF
is found to promote inflammatory reactions by mobilizing
leukocytes (25). Furthermore, VEGF itself was reported to
upregulate endocan expression (18). This link was endorsed by the results of the present study where a statistically
significant positive (direct) correlation between endocan
and VEGF was found during the dynamic phase of the disease as an increase in endocan level was associated with
an increase in VEGF level and vice versa.
Morover, VEGF is considered as a potent angiogenic
factor in the pathogenesis of vasculitis of aphthous ulcers which are characterized by great angiogenic action
and a loss of the epithelial integrity in the oral mucosa
(36). Hence, anti-angiogenic treatments as thalidomide
have been proposed to endorse healing of oral ulcers and
to control the frequency of recurrences (14). Moreover,
VEGF induces vascular thrombosis and inflammation

via stimulating endothelial cells causing the release of
vasoactive substances (37).
While investigating VEGF levels in the present study
mean levels of VEGF was statistically significantly higher in diseased side than control side either at second
day or at day ten. Moreover, the ulcer swabs showed
statistically significantly higher mean VEGF levels at
the second day of ulcer activity than those at the tenth
day during the healing phase. This evident association
linking VEGF to the ulcerative process identified in our
study is consistent with former studies associating the
levels of VEGF with oral aphthous ulceration and with
proof from other ulcer-related disorders as Behçet Disease where clinical proof advocates that VEGF could
be directly involved in oral ulcers formation in Behçet
Disease (11,14,37,38). Finally, an association between
the genetic pathway of VEGF and the occurrence of oral
ulcers have been recognized and validated the in Systemic Lupus Erythematosus (39).
Furthermore, topical steroidal and non-steroidal therapies that have been utilized effectively for the management of RAU are found to considerably affect the VEGF
pathway genes expression designating that the VEGF
pathway might be a significant mediator of the benefits
of immunotherapeutic agents for oral ulcers.

Conclusions

The results of the present investigation revealed a strong
association of Endocan and VEGF levels with the destructive phase of RAU with Endocan levels being more
directly correlated to pain scores. Furthermore a significant positive correlation between Endocan levels and
VEGF levels was evident validating the interrelation between these two markers during the ulcerative process.
Therefore, our findings suggest that the Endocan and
VEGF interconnection along with their association with
the phase of active destruction might offer new insights
for a novel anti-inflammatory strategy of oral RAU that
might allow more specific remedy while avoiding the
detrimental side effects of existing therapies.
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